NASDAQ:ICPT

Intercept Pharmaceuticals Competitors

$21.20
-0.34 (-1.58 %)
(As of 04/22/2021 12:00 AM ET)
Add
Compare
Today's Range
$20.96
Now: $21.20
$21.89
50-Day Range
$19.33
MA: $22.12
$24.88
52-Week Range
$18.15
Now: $21.20
$95.98
Volume734,045 shs
Average Volume1.17 million shs
Market Capitalization$703.03 million
P/E RatioN/A
Dividend YieldN/A
Beta1.85

Competitors

Intercept Pharmaceuticals (NASDAQ:ICPT) Vs. AMGN, GILD, VRTX, REGN, BIIB, and ALXN

Should you be buying ICPT stock or one of its competitors? Companies in the sub-industry of "biotechnology" are considered alternatives and competitors to Intercept Pharmaceuticals, including Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), and Alexion Pharmaceuticals (ALXN).

Amgen (NASDAQ:AMGN) and Intercept Pharmaceuticals (NASDAQ:ICPT) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, institutional ownership, dividends, profitability, valuation and analyst recommendations.

Profitability

This table compares Amgen and Intercept Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Amgen29.42%95.55%15.52%
Intercept Pharmaceuticals-106.64%-1,973.10%-48.51%

Valuation and Earnings

This table compares Amgen and Intercept Pharmaceuticals' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Amgen$23.36 billion6.29$7.84 billion$14.8217.21
Intercept Pharmaceuticals$252 million2.79$-344,680,000.00($10.89)-1.95

Amgen has higher revenue and earnings than Intercept Pharmaceuticals. Intercept Pharmaceuticals is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

75.2% of Amgen shares are held by institutional investors. Comparatively, 85.8% of Intercept Pharmaceuticals shares are held by institutional investors. 0.4% of Amgen shares are held by company insiders. Comparatively, 23.7% of Intercept Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Analyst Ratings

This is a summary of recent recommendations for Amgen and Intercept Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Amgen091402.61
Intercept Pharmaceuticals115802.29

Amgen presently has a consensus target price of $261.1429, suggesting a potential upside of 2.38%. Intercept Pharmaceuticals has a consensus target price of $50.6957, suggesting a potential upside of 139.02%. Given Intercept Pharmaceuticals' higher probable upside, analysts clearly believe Intercept Pharmaceuticals is more favorable than Amgen.

Risk and Volatility

Amgen has a beta of 0.76, suggesting that its share price is 24% less volatile than the S&P 500. Comparatively, Intercept Pharmaceuticals has a beta of 1.85, suggesting that its share price is 85% more volatile than the S&P 500.

Summary

Amgen beats Intercept Pharmaceuticals on 10 of the 14 factors compared between the two stocks.

Gilead Sciences (NASDAQ:GILD) and Intercept Pharmaceuticals (NASDAQ:ICPT) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, institutional ownership, dividends, profitability, valuation and analyst recommendations.

Profitability

This table compares Gilead Sciences and Intercept Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Gilead Sciences5.48%37.77%12.76%
Intercept Pharmaceuticals-106.64%-1,973.10%-48.51%

Valuation and Earnings

This table compares Gilead Sciences and Intercept Pharmaceuticals' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Gilead Sciences$22.45 billion3.68$5.39 billion$6.1410.69
Intercept Pharmaceuticals$252 million2.79$-344,680,000.00($10.89)-1.95

Gilead Sciences has higher revenue and earnings than Intercept Pharmaceuticals. Intercept Pharmaceuticals is trading at a lower price-to-earnings ratio than Gilead Sciences, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

76.4% of Gilead Sciences shares are held by institutional investors. Comparatively, 85.8% of Intercept Pharmaceuticals shares are held by institutional investors. 0.1% of Gilead Sciences shares are held by company insiders. Comparatively, 23.7% of Intercept Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Analyst Ratings

This is a summary of recent recommendations for Gilead Sciences and Intercept Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Gilead Sciences191302.52
Intercept Pharmaceuticals115802.29

Gilead Sciences presently has a consensus target price of $97.68, suggesting a potential upside of 48.79%. Intercept Pharmaceuticals has a consensus target price of $50.6957, suggesting a potential upside of 139.02%. Given Intercept Pharmaceuticals' higher probable upside, analysts clearly believe Intercept Pharmaceuticals is more favorable than Gilead Sciences.

Risk and Volatility

Gilead Sciences has a beta of 0.51, suggesting that its share price is 49% less volatile than the S&P 500. Comparatively, Intercept Pharmaceuticals has a beta of 1.85, suggesting that its share price is 85% more volatile than the S&P 500.

Summary

Gilead Sciences beats Intercept Pharmaceuticals on 10 of the 14 factors compared between the two stocks.

Vertex Pharmaceuticals (NASDAQ:VRTX) and Intercept Pharmaceuticals (NASDAQ:ICPT) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, risk, earnings, institutional ownership, valuation, dividends and profitability.

Profitability

This table compares Vertex Pharmaceuticals and Intercept Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Vertex Pharmaceuticals38.51%28.55%20.68%
Intercept Pharmaceuticals-106.64%-1,973.10%-48.51%

Volatility and Risk

Vertex Pharmaceuticals has a beta of 0.79, indicating that its stock price is 21% less volatile than the S&P 500. Comparatively, Intercept Pharmaceuticals has a beta of 1.85, indicating that its stock price is 85% more volatile than the S&P 500.

Institutional & Insider Ownership

92.2% of Vertex Pharmaceuticals shares are held by institutional investors. Comparatively, 85.8% of Intercept Pharmaceuticals shares are held by institutional investors. 0.7% of Vertex Pharmaceuticals shares are held by insiders. Comparatively, 23.7% of Intercept Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares Vertex Pharmaceuticals and Intercept Pharmaceuticals' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Vertex Pharmaceuticals$4.16 billion13.43$1.18 billion$4.2950.34
Intercept Pharmaceuticals$252 million2.79$-344,680,000.00($10.89)-1.95

Vertex Pharmaceuticals has higher revenue and earnings than Intercept Pharmaceuticals. Intercept Pharmaceuticals is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings for Vertex Pharmaceuticals and Intercept Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Vertex Pharmaceuticals042112.88
Intercept Pharmaceuticals115802.29

Vertex Pharmaceuticals currently has a consensus price target of $293.2083, indicating a potential upside of 35.76%. Intercept Pharmaceuticals has a consensus price target of $50.6957, indicating a potential upside of 139.02%. Given Intercept Pharmaceuticals' higher probable upside, analysts clearly believe Intercept Pharmaceuticals is more favorable than Vertex Pharmaceuticals.

Summary

Vertex Pharmaceuticals beats Intercept Pharmaceuticals on 12 of the 15 factors compared between the two stocks.

Regeneron Pharmaceuticals (NASDAQ:REGN) and Intercept Pharmaceuticals (NASDAQ:ICPT) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, risk, earnings, institutional ownership, valuation, dividends and profitability.

Profitability

This table compares Regeneron Pharmaceuticals and Intercept Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Regeneron Pharmaceuticals38.28%28.97%20.11%
Intercept Pharmaceuticals-106.64%-1,973.10%-48.51%

Volatility and Risk

Regeneron Pharmaceuticals has a beta of 0.3, indicating that its stock price is 70% less volatile than the S&P 500. Comparatively, Intercept Pharmaceuticals has a beta of 1.85, indicating that its stock price is 85% more volatile than the S&P 500.

Institutional & Insider Ownership

85.0% of Regeneron Pharmaceuticals shares are held by institutional investors. Comparatively, 85.8% of Intercept Pharmaceuticals shares are held by institutional investors. 11.8% of Regeneron Pharmaceuticals shares are held by insiders. Comparatively, 23.7% of Intercept Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares Regeneron Pharmaceuticals and Intercept Pharmaceuticals' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Regeneron Pharmaceuticals$7.86 billion6.68$2.12 billion$21.4722.84
Intercept Pharmaceuticals$252 million2.79$-344,680,000.00($10.89)-1.95

Regeneron Pharmaceuticals has higher revenue and earnings than Intercept Pharmaceuticals. Intercept Pharmaceuticals is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings for Regeneron Pharmaceuticals and Intercept Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Regeneron Pharmaceuticals051412.80
Intercept Pharmaceuticals115802.29

Regeneron Pharmaceuticals currently has a consensus price target of $644.1739, indicating a potential upside of 31.90%. Intercept Pharmaceuticals has a consensus price target of $50.6957, indicating a potential upside of 139.02%. Given Intercept Pharmaceuticals' higher probable upside, analysts clearly believe Intercept Pharmaceuticals is more favorable than Regeneron Pharmaceuticals.

Summary

Regeneron Pharmaceuticals beats Intercept Pharmaceuticals on 11 of the 15 factors compared between the two stocks.

Biogen (NASDAQ:BIIB) and Intercept Pharmaceuticals (NASDAQ:ICPT) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, risk, earnings, institutional ownership, valuation, dividends and profitability.

Profitability

This table compares Biogen and Intercept Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Biogen35.63%51.00%23.54%
Intercept Pharmaceuticals-106.64%-1,973.10%-48.51%

Volatility and Risk

Biogen has a beta of 0.53, indicating that its stock price is 47% less volatile than the S&P 500. Comparatively, Intercept Pharmaceuticals has a beta of 1.85, indicating that its stock price is 85% more volatile than the S&P 500.

Institutional & Insider Ownership

83.5% of Biogen shares are held by institutional investors. Comparatively, 85.8% of Intercept Pharmaceuticals shares are held by institutional investors. 0.5% of Biogen shares are held by insiders. Comparatively, 23.7% of Intercept Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares Biogen and Intercept Pharmaceuticals' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Biogen$14.38 billion2.74$5.89 billion$33.577.72
Intercept Pharmaceuticals$252 million2.79$-344,680,000.00($10.89)-1.95

Biogen has higher revenue and earnings than Intercept Pharmaceuticals. Intercept Pharmaceuticals is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings for Biogen and Intercept Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Biogen5141202.23
Intercept Pharmaceuticals115802.29

Biogen currently has a consensus price target of $303.3103, indicating a potential upside of 17.00%. Intercept Pharmaceuticals has a consensus price target of $50.6957, indicating a potential upside of 139.02%. Given Intercept Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Intercept Pharmaceuticals is more favorable than Biogen.

Summary

Biogen beats Intercept Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

Alexion Pharmaceuticals (NASDAQ:ALXN) and Intercept Pharmaceuticals (NASDAQ:ICPT) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, risk, earnings, institutional ownership, valuation, dividends and profitability.

Profitability

This table compares Alexion Pharmaceuticals and Intercept Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Alexion Pharmaceuticals16.32%23.16%14.76%
Intercept Pharmaceuticals-106.64%-1,973.10%-48.51%

Volatility and Risk

Alexion Pharmaceuticals has a beta of 1.33, indicating that its stock price is 33% more volatile than the S&P 500. Comparatively, Intercept Pharmaceuticals has a beta of 1.85, indicating that its stock price is 85% more volatile than the S&P 500.

Institutional & Insider Ownership

87.3% of Alexion Pharmaceuticals shares are held by institutional investors. Comparatively, 85.8% of Intercept Pharmaceuticals shares are held by institutional investors. 4.0% of Alexion Pharmaceuticals shares are held by insiders. Comparatively, 23.7% of Intercept Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares Alexion Pharmaceuticals and Intercept Pharmaceuticals' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Alexion Pharmaceuticals$4.99 billion7.42$2.40 billion$9.7417.21
Intercept Pharmaceuticals$252 million2.79$-344,680,000.00($10.89)-1.95

Alexion Pharmaceuticals has higher revenue and earnings than Intercept Pharmaceuticals. Intercept Pharmaceuticals is trading at a lower price-to-earnings ratio than Alexion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings for Alexion Pharmaceuticals and Intercept Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Alexion Pharmaceuticals017412.27
Intercept Pharmaceuticals115802.29

Alexion Pharmaceuticals currently has a consensus price target of $153.4286, indicating a potential downside of 8.44%. Intercept Pharmaceuticals has a consensus price target of $50.6957, indicating a potential upside of 139.02%. Given Intercept Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Intercept Pharmaceuticals is more favorable than Alexion Pharmaceuticals.

Summary

Alexion Pharmaceuticals beats Intercept Pharmaceuticals on 10 of the 15 factors compared between the two stocks.


Intercept Pharmaceuticals Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Amgen logo
AMGN
Amgen
2.3$255.05-1.5%$146.86 billion$23.36 billion20.57Upcoming Earnings
Analyst Report
Analyst Revision
Gilead Sciences logo
GILD
Gilead Sciences
2.8$65.64-1.8%$82.64 billion$22.45 billion67.67Upcoming Earnings
Analyst Report
Analyst Revision
Vertex Pharmaceuticals logo
VRTX
Vertex Pharmaceuticals
2.2$215.98-1.8%$55.90 billion$4.16 billion27.27Upcoming Earnings
Analyst Report
Analyst Revision
News Coverage
Regeneron Pharmaceuticals logo
REGN
Regeneron Pharmaceuticals
2.6$490.43-3.3%$54.26 billion$7.86 billion17.93Analyst Report
Biogen logo
BIIB
Biogen
1.9$259.00-4.2%$41.11 billion$14.38 billion8.57Earnings Announcement
Analyst Report
Analyst Revision
News Coverage
Alexion Pharmaceuticals logo
ALXN
Alexion Pharmaceuticals
1.7$167.65-0.5%$37.04 billion$4.99 billion39.17News Coverage
Seagen logo
SGEN
Seagen
1.7$143.65-2.7%$26.04 billion$916.71 million56.56Upcoming Earnings
Analyst Revision
Exact Sciences logo
EXAS
Exact Sciences
1.8$129.97-0.9%$21.98 billion$876.29 million-58.81Analyst Upgrade
Incyte logo
INCY
Incyte
1.6$84.18-0.6%$18.63 billion$2.16 billion-53.62Analyst Revision
Alnylam Pharmaceuticals logo
ALNY
Alnylam Pharmaceuticals
1.8$137.77-0.2%$16.16 billion$219.75 million-17.60Upcoming Earnings
Analyst Report
Insider Selling
Analyst Revision
News Coverage
Novavax logo
NVAX
Novavax
1.4$207.30-2.7%$15.31 billion$18.66 million-39.71Insider Selling
BioMarin Pharmaceutical logo
BMRN
BioMarin Pharmaceutical
2.1$79.70-0.5%$14.49 billion$1.70 billion18.24Upcoming Earnings
Analyst Report
Insider Selling
News Coverage
Repligen logo
RGEN
Repligen
1.5$216.32-0.6%$11.92 billion$270.24 million263.80Analyst Report
United Therapeutics logo
UTHR
United Therapeutics
1.5$209.33-1.2%$9.44 billion$1.45 billion19.80News Coverage
Neurocrine Biosciences logo
NBIX
Neurocrine Biosciences
2.3$96.51-0.5%$9.17 billion$788.10 million103.78Analyst Report
Unusual Options Activity
Analyst Revision
Exelixis logo
EXEL
Exelixis
1.9$24.66-0.0%$7.72 billion$967.78 million51.38Analyst Report
Halozyme Therapeutics logo
HALO
Halozyme Therapeutics
1.5$49.30-0.9%$7.00 billion$195.99 million308.13
Ionis Pharmaceuticals logo
IONS
Ionis Pharmaceuticals
1.6$42.46-2.3%$5.84 billion$1.12 billion88.46Analyst Report
Analyst Revision
Arena Pharmaceuticals logo
ARNA
Arena Pharmaceuticals
1.7$66.81-1.4%$4.09 billion$806.43 million-9.46Analyst Report
Emergent BioSolutions logo
EBS
Emergent BioSolutions
2.2$63.12-4.6%$3.54 billion$1.11 billion20.30Upcoming Earnings
News Coverage
Alkermes logo
ALKS
Alkermes
1.2$20.92-2.0%$3.26 billion$1.17 billion-45.48Upcoming Earnings
Insider Selling
Analyst Revision
ChemoCentryx logo
CCXI
ChemoCentryx
1.6$46.26-0.4%$3.24 billion$36.13 million-69.04News Coverage
OPKO Health logo
OPK
OPKO Health
1.9$4.37-0.7%$2.93 billion$901.90 million-24.28News Coverage
Amicus Therapeutics logo
FOLD
Amicus Therapeutics
1.6$9.87-1.0%$2.61 billion$182.24 million-8.58Analyst Upgrade
Insider Selling
Ligand Pharmaceuticals logo
LGND
Ligand Pharmaceuticals
1.6$147.98-2.8%$2.53 billion$120.28 million-149.47Decrease in Short Interest
News Coverage
Myriad Genetics logo
MYGN
Myriad Genetics
1.0$28.96-2.9%$2.16 billion$638.60 million-11.14Insider Selling
BioCryst Pharmaceuticals logo
BCRX
BioCryst Pharmaceuticals
1.3$12.05-3.2%$2.07 billion$48.83 million-15.86
Madrigal Pharmaceuticals logo
MDGL
Madrigal Pharmaceuticals
1.7$129.29-0.7%$2.06 billionN/A-11.68
Ironwood Pharmaceuticals logo
IRWD
Ironwood Pharmaceuticals
1.6$10.81-0.4%$1.75 billion$428.41 million15.67Analyst Upgrade
Unusual Options Activity
News Coverage
Sangamo Therapeutics logo
SGMO
Sangamo Therapeutics
1.3$11.85-0.2%$1.71 billion$102.43 million-19.75News Coverage
Codexis logo
CDXS
Codexis
1.3$23.88-0.1%$1.54 billion$68.46 million-68.23Analyst Report
ImmunoGen logo
IMGN
ImmunoGen
1.5$7.76-2.3%$1.51 billion$82.27 million-18.93
Innoviva logo
INVA
Innoviva
1.4$12.02-0.6%$1.23 billion$261.02 million6.13
MannKind logo
MNKD
MannKind
1.4$4.81-4.0%$1.15 billion$63.04 million-22.90News Coverage
Dynavax Technologies logo
DVAX
Dynavax Technologies
1.7$9.54-1.6%$1.08 billion$35.22 million-6.96
Celldex Therapeutics logo
CLDX
Celldex Therapeutics
1.8$26.75-0.1%$1.06 billion$3.57 million-12.00
Curis logo
CRIS
Curis
1.3$10.52-1.4%$949.05 million$10 million-12.83
Vanda Pharmaceuticals logo
VNDA
Vanda Pharmaceuticals
1.5$17.03-0.2%$933.01 million$227.19 million47.31Analyst Downgrade
News Coverage
Bolt Biotherapeutics logo
BOLT
Bolt Biotherapeutics
1.6$24.12-0.5%$872.24 millionN/A0.00
Lexicon Pharmaceuticals logo
LXRX
Lexicon Pharmaceuticals
1.6$5.14-1.0%$734.76 million$322.07 million-4.90Upcoming Earnings
ZIOPHARM Oncology logo
ZIOP
ZIOPHARM Oncology
1.3$3.35-0.0%$720.94 million$150,000.00-4.79News Coverage
Rigel Pharmaceuticals logo
RIGL
Rigel Pharmaceuticals
1.6$3.66-0.8%$627.75 million$59.29 million-24.40Increase in Short Interest
Clovis Oncology logo
CLVS
Clovis Oncology
1.2$6.09-1.5%$627.39 million$143.01 million-1.16
Agenus logo
AGEN
Agenus
1.6$2.92-0.0%$597.68 million$150.05 million-2.68
Molecular Templates logo
MTEM
Molecular Templates
2.0$8.93-2.4%$488.77 million$22.27 million-4.38Analyst Report
Insider Buying
Analyst Revision
News Coverage
Verastem logo
VSTM
Verastem
1.1$2.82-0.0%$484.10 million$17.46 million-2.00
Geron logo
GERN
Geron
1.4$1.49-0.7%$471.43 million$460,000.00-4.26
Spectrum Pharmaceuticals logo
SPPI
Spectrum Pharmaceuticals
1.5$2.99-0.7%$461.95 million$109.33 million-2.20
XOMA logo
XOMA
XOMA
1.5$36.70-1.3%$418.46 million$18.37 million-33.06Increase in Short Interest
Fortress Biotech logo
FBIO
Fortress Biotech
1.6$4.30-2.3%$398.61 million$36.63 million-5.06Analyst Report
This page was last updated on 4/22/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.